Please use a minimum of three unique search wordsOur search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Forsteo ® (teriparatide)
This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information:
Forsteo Summary of Product Characteristics (SmPC)
Forsteo® (teriparatide): Use in Patients with Myeloma
Use of Forsteo in patients with multiple myeloma is not approved.
Patients with skeletal malignancies or bone metastases should be excluded from treatment with teriparatide (contraindication).1
Osteoporosis or pathological fracture may be one of the first signs of multiple myeloma. Rapidly declining bone mineral density or low trauma pathological fracture may warrant further evaluation, including testing for monoclonal gammopathy.2
1. Forsteo [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.
2. Faiman B, Licata AA. New tools for detecting occult monoclonal gammopathy, a cause of secondary osteoporosis. Cleve Clin J Med. 2010;77(4):273-278. https://mdedge-files-live.s3.us-east-2.amazonaws.com/files/s3fs-public/issues/articles/media_12ffa61_273.pdf
Date of Last Review: March 03, 2020
Contact Lilly
Call or Email us
If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com
Available Mon - Fri, 10am - 4pm, excluding Bank Holidays